Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision updated to v3.4.3. The previous revision v3.4.2 was removed.
    Difference
    0.0%
    Check dated 2026-03-12T21:32:26.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. This is a minor metadata update to the page version.
    Difference
    0.0%
    Check dated 2026-02-12T01:39:51.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Minor page update: Revision from v3.4.0 to v3.4.1 with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-04T23:36:19.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    UI changes include showing the glossary option and minor label/versioning updates (e.g., Last Update Submitted that Met QC Criteria vs met QC Criteria; No FEAR Act data vs data) on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-28T19:50:32.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:56:08.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added a dedicated Locations section with site entries in Georgia, New York, Texas, Washington, and Ontario, and updated the page revision to v3.3.3. Removed the older HHS Vulnerability Disclosure link and the prior location sections tied to revision v3.3.2.
    Difference
    0.4%
    Check dated 2025-12-23T20:36:54.000Z thumbnail image

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.